Filtered By:
Condition: Hypertension
Procedure: Heart Transplant

This page shows you your search results in order of date.

Order by Relevance | Date

Total 156 results found since Jan 2013.

McConnell ’ s Bid to Downplay Freezes Undermined by History of Politicians Lying About Their Health
After Senate Minority Leader Mitch McConnell froze during a press conference this month, the Kentucky Republican’s second such episode this summer, his office released a note from the Capitol physician intended to calm those worried about his ability to continue at his job. Dr. Brian Monahan told McConnell in the letter that there was “no evidence that you have a seizure disorder or that you experienced a stroke, TIA or movement disorder such as Parkinson’s disease.” Monahan suggested the episodes may be related to the Leader’s concussion in March or to dehydration.  [time-brightcove n...
Source: TIME: Health - September 11, 2023 Category: Consumer Health News Authors: Mini Racker Tags: Uncategorized Congress Source Type: news

Trends in cardiovascular complications of pregnancy: A nationwide inpatient sample analysis
CONCLUSION: There are concerning increases in certain cardiac complications during pregnancy. This is likely due to increasing age at the time of pregnancy and associated comorbidities.PMID:37678669 | DOI:10.1016/j.amjms.2023.09.001
Source: The American Journal of the Medical Sciences - September 7, 2023 Category: General Medicine Authors: Eric D Warner Saaniya Farhan Matthew Bierowski Farhan Sahawneh Estefania Oliveros Preethi Pirlamarla Stefanie Marek-Iannucci Bhavadharini Ramu Waqas Ullah Yevgeniy Brailovsky Indranee N Rajapreyar Source Type: research

Trends in cardiovascular complications of pregnancy: A Nationwide Inpatient Sample analysis: Trends in cardiovascular complications of pregnancy
CONCLUSION: There are concerning increases in certain cardiac complications during pregnancy. This is likely due to increasing age at the time of pregnancy and associated comorbidities.PMID:37678669 | DOI:10.1016/j.amjms.2023.09.001
Source: The American Journal of the Medical Sciences - September 7, 2023 Category: General Medicine Authors: Eric D Warner Saaniya Farhan Matthew Bierowski Farhan Sahawneh Estefania Oliveros Preethi Pirlamarla Stefanie Marek-Iannucci Bhavadharini Ramu Waqas Ullah Yevgeniy Brailovsky Indranee N Rajapreyar Source Type: research

New artificial intelligence program could help treat hypertension
For the nearly half of Americans with hypertension, it ' s a potential death sentence; it increases the risk of stroke and chronic heart failure. While it ' s relatively easy to prevent or moderate if caught early — eat well, exercise more, consume less…
Source: NSF News - August 1, 2023 Category: Science Authors: NSF Source Type: news

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
CONCLUSIONS: There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM. The available evidence is overall of very low certainty and high risk of bias. We have identified an area of large uncertainty for a group of patients who account for most of those diagnosed as having CKD.PMID:37466151 | DOI:10.1002/14651858.CD007751.pub3
Source: Cochrane Database of Systematic Reviews - July 19, 2023 Category: General Medicine Authors: Tess E Cooper Claris Teng David J Tunnicliffe Brydee A Cashmore Giovanni Fm Strippoli Source Type: research

Pulmonary artery compliance in different forms of pulmonary hypertension
Conclusion PAC was similar between PH groups and was not an independent predictor of transplant-free survival in PAH. RC time was different between PH subgroups, challenging RC time constancy. Trial registration number NCT04071327
Source: Heart - June 26, 2023 Category: Cardiology Authors: McCormick, A., Krishnan, A., Badesch, D., Benza, R. L., Bull, T. M., De Marco, T., Feldman, J., Hemnes, A. R., Hirsch, R., Horn, E., Kennedy, J., Mathai, S. C., McConnell, W., Pugliese, S. C., Sager, J. S., Shlobin, O. A., Simon, M. A., Lammi, M. R. Tags: Pulmonary vascular disease Source Type: research

Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation
ConclusionsElevated plasma levels of ADM may be a marker of pressure/volume overload in HF patients with PH, as well as long-term prognosis after HT. In line with previous studies, our findings additionally confirm that ADM may be a marker of venous congestion in HF. Further studies are encouraged to establish a deeper understanding of the properties of ADM and its relationship with HF and PH, in order to potentially facilitate clinical management of HF and associated PH.
Source: ESC Heart Failure - May 29, 2023 Category: Cardiology Authors: Abdulla Ahmed, Kriss Kania, Hebba Abdul Rahim, Salaheldin Ahmed, G öran Rådegran Tags: Original Article Source Type: research

Artificial Intelligence for the Detection and Treatment of Atrial Fibrillation
AF, the most common clinically relevant cardiac arrhythmia, is expected to affect>5 million Americans by 2050.1 The diagnosis is frequently associated with other cardiovascular comorbidities, including hypertension, obesity and sleep apnoea, and AF is an important risk factor for stroke, heart failure and overall mortality.2 –4 Although treatment is available, many people remain untreated becau...
Source: Radcliffe Cardiology - April 19, 2023 Category: Cardiology Authors: c242508f1d9059bc0f2aa9bdd5421ba2 Source Type: research

Cardiac transplant and exercise cardiac rehabilitation
AbstractCardiac transplantation is the final therapeutic option for patients with end-stage heart failure. Most patients experience a favorable functional ability post-transplant. However, episodes of acute rejection, and multiple comorbidities such as hypertension, diabetes mellitus, chronic kidney disease and cardiac allograft vasculopathy are common. The number of transplants has increased steadily over the past two decades with 3,817 operations performed in the United States in 2021. Patients have abnormal exercise physiologic responses related to surgical cardiac denervation, diastolic dysfunction, and the legacy of r...
Source: Heart Failure Reviews - April 4, 2023 Category: Cardiology Source Type: research

Clonal Hematopoiesis and the Heart: a Toxic Relationship
Curr Oncol Rep. 2023 Mar 15. doi: 10.1007/s11912-023-01398-1. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Clonal hematopoiesis (CH) refers to the expansion of hematopoietic stem cell clones and their cellular progeny due to somatic mutations, mosaic chromosomal alterations (mCAs), or copy number variants which naturally accumulate with age. CH has been linked to increased risk of blood cancers, but CH has also been linked to adverse cardiovascular outcomes.RECENT FINDINGS: A combination of clinical outcome studies and mouse models have offered strong evidence that CH mutations either correlate with or cause atheroscle...
Source: Atherosclerosis - March 15, 2023 Category: Cardiology Authors: Jeffrey L Jensen Saumya Easaw Travis Anderson Yash Varma Jiandong Zhang Brian C Jensen Catherine C Coombs Source Type: research

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news